Shield Therapeutics (LSE:STX) EV-to-EBIT : -0.08 (As of Apr. 27, 2024)

View and export this data going back to 2016. Start your Free Trial

What is Shield Therapeutics EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Shield Therapeutics's Enterprise Value is £2.74 Mil. Shield Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was £-36.31 Mil. Therefore, Shield Therapeutics's EV-to-EBIT for today is -0.08.

The historical rank and industry rank for Shield Therapeutics's EV-to-EBIT or its related term are showing as below:

LSE:STX' s EV-to-EBIT Range Over the Past 10 Years
Min: -41.99 Med: -10.39 Max: 0.03
Current: -0.08

During the past 9 years, the highest EV-to-EBIT of Shield Therapeutics was 0.03. The lowest was -41.99. And the median was -10.39.

LSE:STX's EV-to-EBIT is ranked worse than
100% of 668 companies
in the Drug Manufacturers industry
Industry Median: 17.125 vs LSE:STX: -0.08

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Shield Therapeutics's Enterprise Value for the quarter that ended in Jun. 2023 was £40.31 Mil. Shield Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was £-36.31 Mil. Shield Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was -90.08%.

Shield Therapeutics EV-to-EBIT Historical Data

The historical data trend for Shield Therapeutics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shield Therapeutics EV-to-EBIT Chart

Shield Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EV-to-EBIT

Get a 7-Day Free Trial

-5.05

-22.69

-38.06

-4.23

-0.54

Shield Therapeutics Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
EV-to-EBIT	Get a 7-Day Free Trial													-	-4.23	-	-0.54	-

Competitive Comparison of Shield Therapeutics's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Shield Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shield Therapeutics's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shield Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Shield Therapeutics's EV-to-EBIT falls into.

Shield Therapeutics EV-to-EBIT Calculation

Shield Therapeutics's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	2.736	/	-36.308
	=	-0.08

Shield Therapeutics's current Enterprise Value is £2.74 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Shield Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was £-36.31 Mil.

Shield Therapeutics (LSE:STX) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Shield Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Jun. 2023 )	=	EBIT	/	Enterprise Value (Q: Jun. 2023 )
	=	-36.308	/	40.30793
	=	-90.08 %

Shield Therapeutics's Enterprise Value for the quarter that ended in Jun. 2023 was £40.31 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Shield Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was £-36.31 Mil.

Shield Therapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Shield Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Shield Therapeutics (LSE:STX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shield Therapeutics PLC (LSE:STX) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

SHIEF:USA 1JS:Germany

Address

Northern Design Centre, Baltic Business Quarter, Gateshead Quays, Newcastle, GBR, NE8 3DF

Website

https://www.shieldtherapeutics.com

Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals which address areas of high unmet medical need. The company's operating segments are based on key products including Accrufer/Feraccru, used as a novel oral treatment for iron deficiency anemia in patients, which is commercially available, and PT20 used in treating hyperphosphatemia, which is in its last stage of completion. The company generates maximum revenue from Feraccru segment.